financial guidance

The company's quarterly revenue of $13.2 million and net loss of $.21 per share beat analysts' estimates. 

The company said revenues from its ConfirmMDx prostate cancer test rose 62 percent in 2015, and that testing volume exceeded 15,000 patients.

On an adjusted basis and at constant exchange rates, Q4 revenues increased about 3 percent year over year, but fell short of previously stated guidance of 5 percent growth.

The company's net earnings rose, and it reaffirmed its guidance of $195 million to $200 million in revenues for full year 2016.

Danaher's full-year revenues rose nearly 8 percent with its life sciences and diagnostics business its best-earning segment for both Q4 and FY2015.

The company projects revenues will rise 39 percent year over year in Q4, and 53 percent year over year for 2015.

The firm also reaffirmed is guidance for EPS for the fourth quarter of 2015 in advance of an investor meeting in New York.

Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.

For the quarter ended Sept. 30, Cepheid reported preliminary revenue of approximately $126.5 million, shy of the Wall Street estimate of $127.8 million.

The lower preliminary revenue was due to lower than expected sales of its desktop instruments and performance in Europe and Asia Pacific.